Related Experiment Video

Updated: Jun 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation

Nadia Boufaied1, My-Anh Wioland, Pierre Falardeau

  • 1Thallion Pharmaceuticals Inc., 7150 Alexander-Fleming, Montreal, Quebec H4S 2C8, Canada.

Anti-Cancer Drugs
|March 12, 2010
PubMed

Insights

TLN-4601, a novel farnesylated compound, demonstrates broad cytotoxic and in-vivo antitumor activity. It inhibits the Ras-MAPK pathway by inducing Raf-1 protein degradation, not by direct kinase inhibition or prenylation interference.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • TLN-4601 is a novel farnesylated dibenzodiazepinone with broad cytotoxic and in-vivo antitumor activity.
  • The Ras-mitogen-activated protein kinase (MAPK) pathway is frequently dysregulated in cancer.
  • Understanding the mechanism of action of novel anticancer agents is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the mechanism by which TLN-4601 exerts its antitumor effects.
  • To determine the impact of TLN-4601 on the Ras-MAPK signaling pathway.
  • To elucidate the specific molecular targets and pathways affected by TLN-4601.

Main Methods:

  • Cytotoxic activity was assessed using the NCI 60 tumor cell line panel.
  • In-vivo antitumor activity was evaluated in xenograft models.
  • Western blot analysis was used to assess phosphorylation of Raf-1, MEK, and ERK1/2.
  • Protein prenylation assays were performed.
  • Elk-1 trans-activation reporter assays were utilized.

Main Results:

  • TLN-4601 exhibited broad cytotoxic activity (low micromol/l) and in-vivo antitumor effects.
  • TLN-4601 prevented epidermal growth factor-induced phosphorylation of Raf-1, MEK, and ERK1/2 in a time- and dose-dependent manner.
  • Inhibition of Ras signaling was not due to direct kinase inhibition or interference with protein prenylation.
  • TLN-4601 was found to induce Raf-1 proteasomal-dependent degradation.
  • The compound inhibits the MEK/ERK pathway at the level of Raf-1.

Conclusions:

  • TLN-4601 inhibits the Ras-MAPK signaling pathway.
  • The mechanism of inhibition involves the induction of Raf-1 proteasomal degradation.
  • TLN-4601 represents a promising novel therapeutic agent targeting the Ras-MAPK pathway through a unique mechanism.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...